2023-06-28 09:45:00
German company “Bayer”.
German drugmaker Bayer said on Wednesday that preliminary tests on 12 volunteers showed that an experimental stem cell treatment for Parkinson’s disease was well tolerated, adding that cells transplanted into their brains survived.
The company stated that the positive results over a year of the first phase of the treatment, which was carried out by Bluerock Therapeutics, encouraged it to develop a treatment test on humans and move it to the second phase out of three.
In the experimental treatment, BLurock researchers derived dopamine-producing neurons from pluripotent stem cells, early-stage cells that can develop into any type of specialized tissue.
When surgically implanted into the brain of a person with Parkinson’s disease, the therapeutic cells restore neural networks damaged by the disease because they are designed for this purpose.
Parkinson’s disease leads to progressive cell damage in the brain and low levels of dopamine.
There is no cure for it and more than ten million people in the world are infected with it.
Bayer acquired Bluerock and another company in 2019 and 2020, respectively, as part of efforts to establish the cell and gene therapy industry.
Last year, it partnered with Mammoth Biosciences of the San Francisco Bay Area to develop gene-enhancing therapeutic tools.
Despite this news, the stock fell on the German Stock Exchange, by 0.64 percent, to 49.94 euros, by 10:54 GMT.
Parkinson’s disease leads to movement disorders that impede the daily activity of the patient
1688104024
#Positive #results #Bayers #trials #treat #Parkinsons #disease